is glp-1 tirzepatide use tripled among non-diabetics, reaching $5.8B in 2022 GLP-1/GIP Tirzepatide Rx | FancyMeds

Weight loss effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with obesity without diabetes: A systematic review

Navigating insurance prescription coverage and understanding copays can be a daunting task for patients

Our findings show that HTG [hypertriglyceridemia] is not a reason to withhold this class of medication from appropriate patients, if they would benefit otherwise, Iverson said

All funding is paid to her institution

JAMA Network Several complementary analysesincluding the largest direct comparison of GLP-1 RAs vs metformin as initial therapysuggest GLP-1 drugs may reduce overall and Alzheimers-type dementias more than metformin in people with type 2 diabetes

Again, the peptide was observed to potentially increase skin density and thickness